BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals Inc. has demonstrated a strong upward trajectory in sales, with a notable increase from 11.4% to 13.9% of global sales in the fourth quarter of 2024, signifying robust market performance. The company’s Orladeyo product has been gaining significant traction, with a remarkable 26% rise in physician willingness to prescribe this oral prophylactic treatment, and revenue projections for Orladeyo have been adjusted upward to between $535 million and $550 million for 2025, reflecting a 24% year-over-year growth at the midpoint. Furthermore, the positive developments in reimbursement dynamics, coupled with sustained efficacy in reducing hereditary angioedema attack rates, support a bullish outlook for BioCryst’s financial growth and market position.

The financial outlook for BioCryst Pharmaceuticals Inc. remains negative due to its persistent losses since inception, with a net loss of $26.8 million for 4Q24 and $88.9 million for FY24, indicating that profitability is still several years away. Moreover, 1Q24 Orladeyo sales are anticipated to be flat or lower, influenced by approximately 50% of patients undergoing an annual reauthorization process, which is expected to impact short-term revenue negatively. Additionally, operational expenses exceeded consensus estimates in 4Q24, driven by higher-than-expected selling, general, and administrative costs, further reflecting financial strain.